The latest research study “Malaria Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global malaria vaccine market size is expected to exhibit a CAGR of around 34% during 2022-2030.
Malaria refers to a disease usually caused by the plasmodium parasite that is transmitted to the human body from the bite of infected mosquitoes. Some of the common symptoms include fatigue, nausea, fever, headaches, chills, etc. The malaria vaccine represents a biological component that stimulates the production of antibodies to mitigate the risk of contracting malaria. In line with this, it can be administered in various ways, such as subcutaneous, intramuscular, and intradermal injections. Furthermore, these vaccines can be widely categorized into an erythrocytic vaccine, a pre-erythrocytic vaccine, and a multi-antigen vaccine.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/malaria-vaccine-market/requestsample
Malaria Vaccine Market Trends and Drivers:
The growing prevalence of malaria, particularly across tropical countries, is primarily driving the malaria vaccine market. Additionally, the launch of favorable policies by government bodies to spread awareness regarding disease prevention, as well as the importance of immunization among consumers, especially in the endemic and rural regions, is further catalyzing the market growth. Besides this, the inflating popularity of pre-erythrocytic vaccines, also known as anti-infective vaccines, that target the plasmodium parasite and prevent progression to chronic blood-stage diseases is acting as another significant growth-inducing factor. Moreover, numerous pharmaceutical companies are focusing on the development of improved and novel malaria vaccines by increasing the clinical trials of several pipeline drugs, which is positively influencing the global market. Apart from this, continuous technological advancements, such as the introduction of novel adjuvants and cutting-edge delivery platforms, extensive R&D activities, and the increasing investments in healthcare infrastructures, are anticipated to fuel the malaria vaccine market over the forecasted period.
Malaria Vaccine Market Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Type:
- Pre-Erythrocytic Vaccine
- Erythrocytic Vaccine
- Multi-Antigen Vaccine
- Others
Breakup by Agent:
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
Breakup by Route of Administration:
- Intramuscular
- Subcutaneous
- Intradermal
- Others
Breakup by Distribution Channel:
- NGO/Non-Profit Organization
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
